Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines

Reuters

2025/11/07

<a href="https://laohu8.com/S/MAZE">Maze Therapeutics</a> Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines

Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease (AMKD), which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581012036"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581012036\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581012036?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581012036","market":"us","top_or_hot":-1,"title":"Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MAZE\">Maze Therapeutics</a> Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maze <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease (AMKD), which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MAZE\">Maze Therapeutics</a> Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maze <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease (AMKD), which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MAZE","symbol_name":"Maze Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6s2hcg:1","article_id":"2581012036","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581012036","pubTimestamp":1762462978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease , which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MAZE":"Maze Therapeutics","BK4007":"制药"},"translate_title":"Maze Therapeutics展示了精准肾脏和代谢疾病药物的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAZE":0.9},"content_text":"Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines\n    \n\n        Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease (AMKD), which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}